{"id":"pd1-t-cells","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cytokine release syndrome"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PD1-T cells work by removing the brakes on the immune system, allowing T cells to recognize and attack cancer cells. This is achieved by modifying T cells to express a chimeric antigen receptor (CAR) that targets the PD-1 receptor on cancer cells, thereby activating the immune system to attack the cancer.","oneSentence":"PD1-T cells are a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:01.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Relapsed or refractory acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT07495215","phase":"PHASE1, PHASE2","title":"A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection","status":"RECRUITING","sponsor":"Yinghua Xu","startDate":"2025-09-11","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT06692959","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2025-06-16","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT03799445","phase":"PHASE2","title":"Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-25","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT07476326","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-06-01","conditions":"Melanoma","enrollment":120},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT05338775","phase":"PHASE1","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-25","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":74},{"nctId":"NCT06821503","phase":"PHASE1, PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":"Advanced Pancreatic Cancer","enrollment":72},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT07457177","phase":"PHASE2","title":"Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL","status":"NOT_YET_RECRUITING","sponsor":"LIANG WANG","startDate":"2026-02-10","conditions":"NK T-Cell Lymphoma","enrollment":40},{"nctId":"NCT02840058","phase":"NA","title":"Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-08-31","conditions":"Cancer","enrollment":295},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT05414032","phase":"PHASE2","title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-12","conditions":"Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)","enrollment":102},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT07411781","phase":"PHASE1","title":"PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-01","conditions":"Colorectal Cancer, Adult","enrollment":25},{"nctId":"NCT07293754","phase":"PHASE1, PHASE2","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Repertoire Immune Medicines","startDate":"2025-12-12","conditions":"Advanced Malignant Solid Tumor","enrollment":150},{"nctId":"NCT05079282","phase":"PHASE1","title":"Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-12-10","conditions":"Relapsed or Refractory T Cell Lymphoma","enrollment":217},{"nctId":"NCT02362997","phase":"PHASE2","title":"Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-04","conditions":"Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma","enrollment":82},{"nctId":"NCT04963283","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-23","conditions":"Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma","enrollment":48},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT05694364","phase":"PHASE1","title":"Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-01-25","conditions":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia","enrollment":3},{"nctId":"NCT07392073","phase":"","title":"Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT03203473","phase":"PHASE2","title":"Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toni Choueiri, MD","startDate":"2017-10-26","conditions":"Renal Cancer","enrollment":85},{"nctId":"NCT05620342","phase":"EARLY_PHASE1","title":"Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-06-21","conditions":"Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT07224022","phase":"PHASE2","title":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"John Strickler, M.D.","startDate":"2026-02","conditions":"Colon Cancer","enrollment":24},{"nctId":"NCT03279692","phase":"PHASE2","title":"Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-07","conditions":"High Grade Meningioma","enrollment":26},{"nctId":"NCT03356470","phase":"","title":"Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-02","conditions":"Melanoma","enrollment":5},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07368270","phase":"PHASE1","title":"Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT06069830","phase":"NA","title":"PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-12-06","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":89},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04995003","phase":"PHASE1","title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-12-07","conditions":"Sarcoma, HER-2 Protein Overexpression, Osteosarcoma","enrollment":25},{"nctId":"NCT03752333","phase":"PHASE2","title":"Trial of Pembrolizumab in Cancer of Unknown Primary","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-02-22","conditions":"Cancer of Unknown Primary Site","enrollment":35},{"nctId":"NCT03578406","phase":"PHASE1","title":"HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-09-01","conditions":"Cervical Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":9},{"nctId":"NCT03333616","phase":"PHASE2","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-28","conditions":"Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder","enrollment":100},{"nctId":"NCT02408861","phase":"PHASE1","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-10-21","conditions":"Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection","enrollment":79},{"nctId":"NCT07077512","phase":"PHASE2","title":"Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)","enrollment":30},{"nctId":"NCT03575793","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Salma Sabbour","startDate":"2018-09-06","conditions":"Lung Cancer, SCLC","enrollment":39},{"nctId":"NCT04139057","phase":"PHASE1, PHASE2","title":"EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2019-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":10},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT07331701","phase":"","title":"Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-01","conditions":"Lung Neoplasms, Tumor Immune Microenvironment","enrollment":60},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":"Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic","enrollment":6},{"nctId":"NCT07330050","phase":"PHASE2","title":"WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":31},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT02210117","phase":"EARLY_PHASE1","title":"Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-25","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7","enrollment":104},{"nctId":"NCT05387512","phase":"","title":"A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-12","conditions":"Lung Cancer","enrollment":59},{"nctId":"NCT06690840","phase":"PHASE2","title":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-03-06","conditions":"Triple Negative Breast Cancer","enrollment":45},{"nctId":"NCT06393361","phase":"PHASE2","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-06-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06075524","phase":"","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2015-06-15","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Lung Carcinoma","enrollment":500},{"nctId":"NCT07300891","phase":"PHASE2","title":"T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-01-31","conditions":"Refractory Solid Cancer Patients Unexposed to Immunotherapy","enrollment":72},{"nctId":"NCT07146230","phase":"PHASE2","title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":52},{"nctId":"NCT04146298","phase":"PHASE1, PHASE2","title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2021-10-21","conditions":"Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06046040","phase":"PHASE1","title":"TmPSMA-02 in mCRPC","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-31","conditions":"Metastatic Castrate-Resistant Prostate Cancer (mCRPC)","enrollment":30},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT06825494","phase":"PHASE1, PHASE2","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-04-08","conditions":"Advanced Solid Tumor","enrollment":194},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT02374242","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-11-04","conditions":"Melanoma, Brain Metastases","enrollment":76},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT07264075","phase":"PHASE3","title":"Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2026-01","conditions":"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","enrollment":780},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT06843434","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-20","conditions":"Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma","enrollment":40},{"nctId":"NCT06251973","phase":"PHASE2","title":"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer","enrollment":37},{"nctId":"NCT07160647","phase":"PHASE2","title":"The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-08-20","conditions":"dMMR/MSI-H-type Rectal Adenocarcinoma","enrollment":29},{"nctId":"NCT07002203","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","status":"RECRUITING","sponsor":"Seqker Biosciences, Inc.","startDate":"2024-03-01","conditions":"Solid Tumors, Advanced Cancer, Recurrent Cancer","enrollment":10},{"nctId":"NCT06400160","phase":"PHASE1, PHASE2","title":"Clinical Trial of TB511 in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Twinpig Biolab, Inc.","startDate":"2026-03","conditions":"NSCLC, Prostate Cancer, Colorectal Cancer","enrollment":12},{"nctId":"NCT05741359","phase":"PHASE1","title":"The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Bioray Laboratories","startDate":"2023-04-25","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":18},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT05389514","phase":"","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Providence Health & Services","startDate":"","conditions":"KRAS G12V Mutant Advanced Epithelial Cancers","enrollment":""},{"nctId":"NCT07240194","phase":"PHASE2","title":"The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Large B-cell Lymphoma, TP53","enrollment":24},{"nctId":"NCT03319940","phase":"PHASE1","title":"Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2017-12-26","conditions":"Small Cell Lung Carcinoma","enrollment":269},{"nctId":"NCT06917573","phase":"PHASE2","title":"PALACE: Cemiplimab Trial According to ctDNA Levels","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-07-29","conditions":"Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte"],"phase":"phase_3","status":"active","brandName":"PD1-T cells","genericName":"PD1-T cells","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"PD1-T cells are a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}